# Diabetes Research Hub — Monitor Report
**Run date:** 2026-09-25 (scheduled review)
**Prior report on file:** 2026-09-24 (yesterday)

---

## File System Status

No pipeline has run since the last review. Every result file checked is at the same age (+1 day) as it was in yesterday's report — nothing new landed in `Analysis/Results/` between 2026-09-24 13:41 UTC and this run.

| File | Last modified | Age | Status |
|---|---|---|---|
| `hub_monitor_report.md` | 2026-07-17 | 70 days | **STALE** — unchanged from yesterday; hub_monitor.py still has not run |
| `Diabetes_Research_Tracker.xlsx` | 2026-07-17 | 70 days | **STALE** — unchanged |
| `clinical_trials_latest.json` | 2026-07-17 | 70 days | **STALE** — unchanged; still stuck, see below |
| `pubmed_recent_latest.json` | 2026-09-23 | 2 days | Aging — no new PubMed pull since 09-23 |
| `literature_gap_data.json` | 2026-09-19 | 6 days | OK |
| `literature_gap_report.md` | 2026-09-24 | 1 day | Fresh, but same underlying data as reported yesterday (report was only re-rendered at 13:40 UTC on 09-24, no new PubMed pull behind it) |
| `RESEARCH_DOCTRINE.md` | 2026-08-31 | 25 days | OK |
| `CONTRIBUTION_STRATEGY.md` | 2026-03-15 | 194 days | Stale but doctrinal |

**Last workspace activity:** 2026-09-24, 13:36–13:41 UTC — a build/audit pass touched `impossible_pmid_audit.json`, `gate_exit_code_audit.json`, `.gap_checkpoint.json`, `builder_compile_audit.json`, `agent_state.json`, and regenerated `literature_gap_report.md` (cosmetic re-render, same 09-19 gap data, same top-5 gaps as yesterday's report). Nothing has run since.

**Anomaly (unresolved from yesterday):** `clinical_trials_latest.json` remains stuck at the Jul 17 run — this is the second consecutive daily review flagging it. Yesterday's recommendation to run `baseline_clinical_trials.py` and check the snapshot-promotion step has not been actioned.

---

## Clinical Trial Changes

No new data — `clinical_trials_latest.json` is unchanged since yesterday. See 2026-09-24's report for the last available comparison (Jul 17 vs. the 2026-09-06 snapshot: 57 new trials, 21 dropped, 26 status changes, including Novo's icodec Phase 3 trial moving to ACTIVE_NOT_RECRUITING and Lilly's orforglipron Phase 3 trial moving to RECRUITING). That analysis is now 8 additional days staler than when first flagged.

## PubMed Highlights

No new pull since 2026-09-23 (now 2 days old). Yesterday's cross-domain and key-therapy findings (17 cross-domain papers; zimislecel at 0 mentions in the 30-day window) stand unchanged — nothing new to add.

## Gap Analysis Summary

Same top 5 gaps as yesterday's report (Beta Cell Regen × Health Equity; Insulin Resistance × Islet Transplant; Islet Transplant × Drug Repurposing; Islet Transplant × Health Equity; Gene Therapy × LADA) — underlying data is still the 2026-09-19 run. No new analysis to report.

## Breaking News

Checked "diabetes breakthrough 2026" and "FDA diabetes approval 2026" (last 7 days). No new items beyond Lilly's Onswik (insulin efsitora alfa-gobe) approval already captured in yesterday's report. One other GLP-1 item surfaced in search (oral Wegovy/semaglutide FDA approval) but that approval dates to 2025-12-22 — old news, not from this window.

## Recommended Actions

Unchanged from yesterday — none of the prior recommendations have been actioned yet:

1. **Diagnose the clinical-trials pipeline** — now 70 days stale, second consecutive day flagged. Run `python baseline_clinical_trials.py` and check the snapshot-to-"latest" promotion step.
2. **Re-run `hub_monitor.py`** — 70 days stale; file-level change tracking across the hub is currently blind.
3. **Refresh PubMed data** — `pubmed_recent_latest.json` is now 2 days old; not urgent yet but trending toward stale.
4. Tracker updates for NCT07076199 (icodec) and the Onswik approval are still outstanding from yesterday.
5. No new gap-analysis or PubMed action needed beyond a refresh — content is unchanged from yesterday.

*This is a review-only run. No existing files were modified.*
